Altasciences Supports Metsera in Their Early Stage Clinical Trials for Obesity

Altasciences is proud to have supported Metsera, Inc., a clinical stage biopharmaceutical company, with nonclinical and early-stage clinical trials. This support includes a recent Phase I/II trial of MET-097i: an ultra-long-acting injectable amylin analog and fully biased GLP-1 receptor agonist.

In a trial conducted at our clinic, Metsera reported positive topline results. This study enabled Metsera to initiate a randomized 16-week Phase II trial of MET-097i, which could offer potential new treatment options for those affected by obesity. We also further supported Metsera with our proactive drug development solution, providing nonclinical, bioanalysis, CRO, and program management services for several other therapeutic candidates.

Altasciences Upholds Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services

A trusted drug development research partner for over 30 years, Altasciences remains committed to providing world-class bioanalytical services in support of the preclinical and clinical studies conducted at our cutting-edge facilities, as well as extensive standalone solutions to meet your diverse needs.

Our flexible bioanalytical services from discovery to Phase IV empower clients across every phase of research.

Let's Promote Your Project!

Interested in a custom press release, written by our experts, to feature the great research we do together? Email us to get started!

You may also be interested in:

• The Altascientist Issue No.42: Managing the Complexities of Glucagon-Like Peptide-1 Receptor Agonist Drug Development
• The Altascientist Issue No.41: Immunomodulation Assessments for Clinical Trials: Sophisticated Bioanalytical Approaches to Support Complex Modalities
• Case Study: GLP-1 RA: Overcoming Known Pharmacological Effects
• Case Study: GLP-1 RA: Rapid Clinical Phase I Study Execution
• Blog: 4 Essential Topics to Cover in Your First CRO Meeting
• Press Releases: View More

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services

We have been your trusted drug development research partner for over 30 years. We are committed to providing world-class bioanalytical services in support of the preclinical and clinical studies conducted at our cutting-edge facilities, as well as extensive standalone solutions to meet your diverse needs. Our flexible bioanalytical services from discovery to Phase IV empower our clients across every phase of research.

We recently launched the Unveiling the Invisible video campaign to showcase how our bioanalytical solutions provide critical insights that unveil the invisible and drive the creation of your innovative therapies.

RELATED RESOURCES

Our bioanalytical team excels in comprehensive bioanalytical services, including assay and method development, molecular biology, mass spectrometry, ligand binding assays, immunogenicity testing, biomarker analysis, flow cytometry services, and more, to support your journey from discovery through Phase IV.

Below are some resources that highlight our extensive knowledge, and wealth of bioanalytical experience.

• The Altascientist Issue 41: Immunomodulation Assessments for Clinical Trials—Sophisticated Bioanalytical Approaches to Support Complex Modalities
• eBook: Key Considerations for Nonclinical AAV Gene Therapy Development
• eBook: Key Biomarkers of Immunomodulation
• Scientific Research Article: A Novel Hybridization LC-MS/MS Methodology for Quantification of siRNA
• Scientific Research Article: A Validated Capillary Microsampling LC-MS Method for Quantification of ASOs in Mouse Serum
• Scientific Research Article: Microsampling in Pediatric Studies

In this issue of The Altascientist, we explore the current and future development of GLP-1 receptor agonists (GLP-1 RAs), and the complexities involved in the early phases.

Topics covered include preclinical models, bioanalytical assays, clinical study design, manufacturing, and the expanding applications of GLP-1 drugs in treating various health conditions. Exclusive case studies are also presented.

Questions about your drug development program? Speak with one of our experts.

• Webinar: The Golden Era of GLP-1 Drugs
• Blog: Five Promising Treatment Areas in Early-Phase Drug Development
• Webpage: Our Comprehensive Drug Development Solutions

The True Meaning of Moving in Unison

We value your time as much as you do. At Altasciences, we break down organizational silos, streamline project management, and promote effortless communication to provide you with exceptional value.

From preclinical studies to clinical trials, and from regulatory submissions to tackling operational challenges, we are dedicated to safely accelerating your journey from lead candidate selection to proof of concept and beyond using a seamless and integrated approach to drug development.

Let's get your project started! Speak with an expert today.

Altasciences’ CNS Center of Excellence is globally renowned for offering expert, fully integrated early phase drug development services. Whether large or small molecule, our streamlined solutions can help move your compound from prototype formulation through to commercialization, delivering up to 40% in time savings.

Our in-house preclinical, clinical, bioanalytical, and manufacturing teams have completed over 200 neurological studies to date. By partnering with us, you benefit from:

•    a CNS research team comprised of neuroscientists, clinicians, psychiatrists, pharmacists, and other interdisciplinary experts;
•    a dedicated preclinical facility with expertise in cell and gene therapy;
•    three state-of-the-art clinical research sites;
•    10 on-site driving simulators for cognitive testing; and
•    300+ scientists for bioanalytical support.

And there’s more! Discover our full range of CNS drug development services here.

 Questions? Contact one of our experts.

Related resources that may interest you:

Scientific Journal: Integrated CNS Drug Development Solutions Lessen Complexities
Webinar: Practical Approaches When Conducting Clinical Trials With Psychedelics
Educational Video: Development Strategies for Neurological Drugs

The process of biologic drug development, from lead molecule identification to approval, can be long and complicated. Altasciences is here to help streamline the process. From discovery to preclinical, clinical, and beyond, Altasciences accelerates decision-making by offering expert guidance and synchronized early phase services to reduce timelines by up to 40%. With Altasciences, your entire program is managed by one organization and overseen by a single, cross-functional program manager to quickly and seamlessly advance your large molecule, and help you get your therapies to the people who need them, faster.

Download now.

You may also be interested in the following:
- Blog: Four Key Steps to Optimizing a Large Molecule Bioanalytical Program.
- Fact Sheet: Biologics/Biosimilars.
- Video: Quick Chat with Dr. Lynne Le Sauteur – The Benefits of Large Molecule Bioanalysis with Altasciences.

From Discovery to Market, We’ve Got You Covered.

As a leading partner in ophthalmic drug development, Altasciences has an outstanding track record formulating, testing, and manufacturing ophthalmic products. Working in tandem with our in-house preclinical, clinical, and bioanalytical teams, we ensure your compound advances safely and rapidly through each phase of drug development―from lead candidate selection to market.

Benefit from integrated CRO/CDMO services and a team that offers: 

•    Development and analytical testing of ophthalmic drug products in various dosage forms at our cGMP manufacturing facility
•    50 years of preclinical experience in ophthalmic safety testing
•    Three North American clinical research sites with over 500 beds and a database of 400,000+ participants
•    Bioanalytical expertise with rare and limited matrices, such as tears

Explore our full range of ophthalmic drug development services, or read the issue of The Altascientist to learn about the key considerations in each phase of ophthalmic drug development, including case studies.

Have questions? Consult with one of our experts. 

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.